AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 81 min read$AXON

Coughlin Elizabeth Reid sold $754K of AXON

Coughlin Elizabeth Reid (Chief Human Officer) sold 1,554 shares of AXON ENTERPRISE, INC. (AXON) at $485.00 ($0.75M total) on 2026-06-04.

Original reporting
SEC EDGAR · Coughlin Elizabeth Reid
Published Jun 8, 2026, 8:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AXON
Neutral
high confidence
Mentioned
$AXON
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXONNeutralLow
01

Why it matters

It documents an officer’s open-market sale; it does not provide new operational, financial, or legal information about Axon.

02

Market read

Traders may note the insider sale, but there is no new company catalyst to drive a sustained repricing.

03

What to watch

Insider sales can be driven by diversification, tax, or personal liquidity needs; without additional filings (buys, options exercises, or material events), signal quality is low.

Relevance 5/10Novelty 2/10Timing: Filed 2026-06-08; sale executed 2026-06-04.

Background

The article is a SEC Form 4 insider transaction disclosure for Axon Enterprise, Inc.

Company-level read

Ticker impact

$AXONNeutralHigh confidence
Context

Axon chief human officer Elizabeth Reid filed an open-market sale of 1,554 shares at $485/share on 2026-06-04 (Form 4).

Expected impact

Low near-term impact; any reaction is likely muted and short-lived.

Evidence & confidence

This is a Form 4 insider transaction with no 10b5-1 plan and no accompanying fundamental disclosure (no guidance, contract, or enforcement action).

Market effects

Sector

Minimal; insider sale does not change sector fundamentals or regulatory outlook.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a 10b5-1 plan could be interpreted as discretionary selling, but the disclosed size is still small relative to typical institutional flows.

Key entities

  • issuer
    AXON ENTERPRISE, INC.

    Company whose insider transaction was reported on SEC Form 4.

  • insider
    Coughlin Elizabeth Reid

    Chief Human Officer who sold 1,554 shares at $485/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AXON insider trading history →

Related articles

AUG 23
$AXONMedAI 8/10

Axon’s AI Era Revenue Jumped Nearly 700%. Here’s What’s Behind It

Axon Enterprise (AXON) reported 35% revenue growth to $904M, beating estimates. AI Era revenue surged nearly 700% YoY. Management raised full-year guidance to 32-34% growth. Gross margin slipped 40 basis points to 62.9%. Analysts estimate a target price of $714, implying 13.7% upside over 2.4 years. The stock trades at 70x forward earnings, with growth driven by software and AI products.

tikr.com3 min
AUG 20
$BABAHighAI 8/10

Breakfast News: Alibaba's AI Push Comes at a Cost

Alibaba's Q1 revenue rose 9% to $39.6B, but operating income fell 57% due to tech investments. BILL Holdings reported 14% revenue growth and 80% operating income increase. U.S. debt surpassed $40T, with Treasury buybacks easing yield pressure. Apple plans 2027 launch for camera AirPods. Axon Enterprise passes competitive position tests, with a 69% potential upside to $1,088.08.

fool.com4 min
AUG 10
$AXONMed

Axon Stock Rebounds As Its Margin Squeeze Looks Like The Price Of Growth

Axon Enterprise (AXON) shares rose 9.3% on Friday after a 14.3% drop the prior session following its Q2 2026 results. The quarter showed revenue of $904 million, up 35% year over year, and a raised full-year outlook. The market disagreed over margin compression tied to higher memory costs and counter-drone hardware mix, with Axon expecting Q3 adjusted EBITDA margin to hold and rebuild in Q4.

finance.yahoo.com4 min
AUG 7
$AXONMed

Raise. So Why Is the Stock Down?

Axon Enterprise (NASDAQ: AXON) reported Q2 revenue of $904M, up 35% year over year, beating estimates of $876.5M. Adjusted EBITDA rose 40% to $242M, and adjusted EPS was $1.88 vs $1.84 expected. Axon raised full-year revenue guidance to 32%-34% growth but reduced software and services gross margin and withdrew operating cash flow and free cash flow guidance.

aol.com4 min